Shanghai Yingrui Biopharma Co.,Ltd.
Home
About Us
ABOUT US
Corporate Culture
Products
APIs & Intermediates
PEG Derivatives
The others
Services
News
Company News
Industry Trends
Contact Us
NEWS CENTER
The total amount of foreign licensing for innovative drugs in China has exceeded 60 billion US dollars
During the "15th Five-Year Plan" period, China's innovative drugs made a promising start in their global expansion. According to the National Medical Products Administration's new incomplete statistics, the total amount of foreign licensing fees for Chinese innovative drugs in the first three months of this year has exceeded US$60 billion.
2026-03-30
2026
03-30
Anti-cancer cutting-edge TIL cell therapy has achieved multiple breakthroughs
TIL cell therapy, also known as tumor-infiltrating lymphocyte therapy, is an innovative cancer treatment method. After years of research and practice, this technology has gradually matured, bringing new hope to patients with advanced cancer.
2026-03-13
03-13
In 2026, multinational pharmaceutical companies intensively partnered
Just two months into 2026, the pharmaceutical industry has already witnessed a surge in collaborations between Chinese and multinational pharmaceutical companies.
2026-02-25
02-25
Domestic innovative drugs have ushered in another "blockbuster drug"
In the field of biomedicine, major products with annual sales exceeding US$1 billion are vividly referred to as "blockbuster" drugs. It is reported that China has welcomed another blockbuster drug, namely Carvykti (Cediranib Injection), a CAR-T product from the Chinese innovative drug company Legend Biologics.
2026-02-06
02-06
Antitumor drugs remain the focus of new drug approvals
In 2025, China's innovative drug sector delivered an impressive performance, with the National Medical Products Administration approving 76 innovative drugs for marketing throughout the year.
2026-01-20
01-20
The intelligent development of the pharmaceutical industry is accelerating once again!
Recently, eight departments including the Ministry of Industry and Information Technology
2026-01-08
01-08
The field of TGCT has ushered in a new era of targeted therapy
Tendon sheath giant cell tumor (TGCT) is a locally invasive disease that can seriously affect the quality of life of patients, causing joint pain, stiffness, swelling, and limited mobility. The working age population is a high-risk group. If left untreated or recurrent, it may lead to irreversible damage to bones, joints, and surrounding tissues. Patients have a huge and unmet clinical need for well tolerated and effective systemic treatment options. Recently, there has been good news in this dr
2025-12-24
2025
12-24
Sinovac and Innovent's blockbuster ophthalmic innovative drugs usher in new progress
Retinal vascular hyperplasia has gradually become one of the important causes of irreversible blindness in adults worldwide. Among them, age-related macular degeneration (nAMD), diabetes macular edema (DME) and other retinal neovascular diseases are particularly harmful.
2025-12-10
12-10
Another domestic new drug has obtained special exemption qualification from the US FDA
Recently, the US FDA officially granted NouvNeu004 Injection, a subsidiary of Ruijian Yilian Pharmaceutical Technology Co., Ltd., special exemption status and further approved the international phase I clinical trial of NouvNeu004 Injection for multiple system atrophy. It is reported that this is a further significant international progress made by NouvNeu004 injection after the National Medical Products Administration (NMPA) of China officially approved the Phase I-III full cycle clinical trial
2025-11-28
11-28
The 93rd API China opened in Chongqing
On November 12, 2025, the highly anticipated 93rd China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Fair (API China) kicked off at the Chongqing International Expo Center.
2025-11-12
11-12